Talphera (TLPH) Total Current Liabilities (2010 - 2026)
Talphera (TLPH) posted Total Current Liabilities of $4.2 million for Q2 2026, up 4.05% on a QoQ basis from $4.0 million in Q1 2026, and up 59.24% year-over-year from $2.6 million in Q2 2025.
Analysis
Talphera (TLPH) Total Current Liabilities (2010 - 2026) Analysis & Trends
Talphera has reported Total Current Liabilities for 17 years, with the latest figure at $4.2 million in Q2 2026.
- On a quarterly basis, Total Current Liabilities rose 59.24% year-over-year to $4.2 million in Q2 2026; TTM through Jun 2026 was $4.2 million, a 59.24% increase from a year earlier, with the FY2025 full-year figure at $3.8 million, up 43.9% from the prior year.
- Total Current Liabilities was $4.2 million for Q2 2026 at Talphera, up from $4.0 million in the prior quarter.
- The five-year high for Total Current Liabilities was $17.7 million in Q2 2022, with the low at $2.0 million in Q1 2025.
- Average Total Current Liabilities over 5 years is $6.5 million, with a median of $3.9 million recorded in 2025.
- The sharpest annual moves came in 2023 and 2026: Total Current Liabilities tumbled 77.16% in 2023, then jumped 102.36% in 2026.
- Over 5 years, Total Current Liabilities stood at $13.8 million in 2022, then sank by 67.23% to $4.5 million in 2023, then tumbled by 41.33% to $2.6 million in 2024, then soared by 43.9% to $3.8 million in 2025, then climbed by 9.95% to $4.2 million in 2026.
- The last three Total Current Liabilities figures came in at $4.2 million (Q2 2026), $4.0 million (Q1 2026), and $3.8 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 25.50 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 11.02 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 3.94 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 5.53 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 1.58 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 2.53 Bn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 1.51 Bn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 3.92 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 283.60 Mn |
| 10 | Talphera | 92.90 Mn | 92.90 Mn | - | 4.19 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 4.19 Mn |
| Mar 31, 2026 | 4.03 Mn |
| Dec 31, 2025 | 3.81 Mn |
| Sep 30, 2025 | 3.21 Mn |
| Jun 30, 2025 | 2.63 Mn |
| Mar 31, 2025 | 1.99 Mn |
| Dec 31, 2024 | 2.65 Mn |
| Sep 30, 2024 | 2.76 Mn |
| Jun 30, 2024 | 3.27 Mn |
| Mar 31, 2024 | 3.34 Mn |
| Dec 31, 2023 | 4.51 Mn |
| Sep 30, 2023 | 3.57 Mn |
| Jun 30, 2023 | 4.22 Mn |
| Mar 31, 2023 | 9.46 Mn |
| Dec 31, 2022 | 13.77 Mn |
| Sep 30, 2022 | 15.65 Mn |
| Jun 30, 2022 | 17.69 Mn |
| Mar 31, 2022 | 17.03 Mn |
| Dec 31, 2021 | 18.51 Mn |
| Sep 30, 2021 | 17.07 Mn |